Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Study reveals new way to ‘rewire’ immune cells to slow tumor growth
Inside a tumor, immune cells and cancer cells battle for survival. The advantage may go to the cells that metabolize the most glucose, say Yale researchers who have identified a new way to boost immune response by metabolically “rewiring” immune cells.
Targeting a Deadly Type of Uterine Cancer
Endometrial cancer, which originates in the lining of the uterus and is the most common type of gynecological cancer, often has a good prognosis. Patients with the more frequently diagnosed type I are often cured. Type II, however, is responsible for most of the recurrences and deaths that occur in endometrial cancer. Uterine Serous Carcinoma (USC), the most aggressive kind of type II endometrial cancer, accounts for just 10 percent of endometrial tumors and is particularly deadly: in its earliest stages the survival rate can be as low as 50 percent, and for those with more advanced disease, there is no cure.
$7.5 Million Grant to Yale Researchers for Role of Viruses in Cancer
The National Cancer Institute recently awarded a five-year, $7.5 million program project grant to investigators at the Yale School of Medicine to continue studies on the role of viruses and mutant cellular proteins in tumorigenic transformation of cells.
PFAS and Phenols Linked to Different Cancers in Women of Different Races
A new federally-funded study in the Journal of Exposure Science & Environmental Epidemiology has found that compounds called phenols, and the synthetic chemicals PFAS, were linked to different kinds of cancer in white women and women of color. PFAS were linked to ovarian and uterine cancers mainly in white women, and phenols were linked more to breast cancer in non-white women. Phenols and PFAS are found in hundreds of daily consumer products. The researchers stated that the racial differences are particularly impactful because of racial disparities in exposure to these chemicals. Nicole Deziel, member of the Yale Cancer Center and associate professor of epidemiology (environmental sciences) at Yale School of Public Health, who is not associated with the study, said the findings “provided a lot of new information suggesting that exposure to PFAS could be associated with a variety of hormonally related cancers, particularly in women.”Source: CT Public Radio
AI More Accurately Identifies Patients With Advanced Lung Cancer Who Respond to Immunotherapy
Researchers compared AI-powered digital scoring with traditional manual scoring of the PD-L1 immune biomarker to determine if a new immunotherapy treatment, atezolizumab, could benefit patients with advanced non-small cell lung cancer.
Breakthrough Targeted Therapy Approach for Non-Small Cell Lung Cancer Helps Patients With a Genetic Mutation Live Longer
Yale Cancer Center researchers at Yale School of Medicine discovered that patients with stage III NSCLC and an EGFR genetic mutation had improved survival outcomes with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) after being treated with chemoradiation.
Engaging People with Low-Grade Glioma in Cancer Research
Some people with low-grade glioma, a type of brain tumor, can live for years, even decades, without the disease worsening. But eventually these cancers start to grow, and little is known about why—or how—this happens. An NCI-supported study called OPTIMUMExit Disclaimer (Optimizing Engagement in Discovery of Molecular Evolution of Low-Grade Glioma) could provide some answers.Source: National Cancer Institute